Trials / Terminated
TerminatedNCT00369395
A Study of Volociximab in Metastatic Melanoma
A Phase 2, Open-Label, Two-Stage Study of Volociximab (M200) for the Treatment of Subjects With Metastatic Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab. Pharmacokinetics and mechanism of action will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | volociximab | Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression. |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2006-08-29
- Last updated
- 2012-04-27
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00369395. Inclusion in this directory is not an endorsement.